All In Biotech

Drug Trial Radar · NCT03399370

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Last checked: Nov 19, 2026Latest source record: Oct 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,561 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,561

Actual

Start

Dec 21, 2017

Primary completion

Sep 10, 2019

Study completion Sep 17, 2019

Sponsor

Lead sponsor
The Medicines CompanyIndustry
Sponsor type
Industry
First posted
Jan 16, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) inclisiran injection(s). The study will be a multicenter study in the United States.

Conditions

  • ASCVD
  • Elevated Cholesterol

Interventions

  • Inclisiran SodiumDrug

    Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.

  • PlaceboDrug

    Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change in LDL-C From Baseline to Day 510Time frame: Baseline, Day 510
  2. Time-adjusted Percentage Change in LDL-C Levels From Baseline After Day 90 and up to Day 540Time frame: Baseline, Day 90 to Day 540

Locations

145 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site 10001-015

    Birmingham, Alabama

  • Research Site 10001-138

    Foley, Alabama

  • Research Site 10001-113

    Huntsville, Alabama

  • Research Site 10001-058

    Mobile, Alabama

  • Research Site 10001-037

    Montgomery, Alabama

  • Research Site 10001-076

    Saraland, Alabama

  • Research Site 10001-013

    Chandler, Arizona

  • Research Site 10001-077

    Mesa, Arizona

  • Research Site 10001-136

    Phoenix, Arizona

  • Research Site 10001-051

    Surprise, Arizona

  • Research Site 10001-019

    Tucson, Arizona

  • Research Site 10001-004

    Tucson, Arizona

  • Research Site 10001-132

    Tucson, Arizona

  • Research Site 10001-073

    Beverly Hills, California

  • Research Site 10001-050

    Canoga Park, California

  • Research Site 10001-011

    Carlsbad, California

  • Research Site 10001-065

    El Cajon, California

  • Research Site 10001-150

    Los Angeles, California

  • Research Site 10001-043

    Northridge, California

  • Research Site 10001-022

    Northridge, California

  • Research Site 10001-033

    Sacramento, California

  • Research Site 10001-105

    San Ramon, California

  • Research Site 10001-008

    Santa Rosa, California

  • Research Site 10001-153

    Spring Valley, California

  • Research Site 10001-044

    Torrance, California

  • Research Site 10001-047

    Boca Raton, Florida

  • Research Site 10001-084

    Clearwater, Florida

  • Research Site 10001-155

    Clearwater, Florida

  • Research Site 10001-099

    Clearwater, Florida

  • Research Site 10001-127

    Daytona Beach, Florida

  • Research Site 10001-119

    Fleming Island, Florida

  • Research Site 10001-070

    Fort Lauderdale, Florida

  • Research Site 10001-067

    Hialeah, Florida

  • Research Site 10001-139

    Jacksonville, Florida

  • Research Site 10001-039

    Jacksonville, Florida

  • Research Site 10001-098

    Jacksonville, Florida

  • Research Site 10001-081

    Miami, Florida

  • Research Site 10001-140

    Miami, Florida

  • Research Site 10001-142

    Miami, Florida

  • Research Site 10001-030

    Miami, Florida

Showing 40 of 145 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.